Patents Assigned to NsGene A/S
-
Publication number: 20170143794Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.Type: ApplicationFiled: September 27, 2016Publication date: May 25, 2017Applicant: NsGene A/SInventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 9474786Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.Type: GrantFiled: September 5, 2012Date of Patent: October 25, 2016Assignee: NsGene A/SInventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 9364427Abstract: The invention provides a device for Encapsulated Cell Therapy. The device includes an implantable capsule containing cells which secrete a biologically active compound for providing a biological function. The capsule has a semi permeable outer membrane for delivery of the compound e.g. at a site in the central nervous system or the spinal cord, e.g. in the brain of a patient. The capsule is connected to a tether which e.g. facilitates removal of the capsule from the patient. To facilitate insertion of the capsule into the patient, a stiffener may be attached to the tether to make the tether more rigid. The invention further provides a container for storing a cell therapy device and a method of locating the device in the body of a patient.Type: GrantFiled: May 15, 2006Date of Patent: June 14, 2016Assignee: NsGene A/SInventors: Lars U. Wahlberg, Jens Tornøe
-
Patent number: 9314502Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: GrantFiled: August 22, 2014Date of Patent: April 19, 2016Assignee: NsGene A/SInventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 9121037Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: May 29, 2014Date of Patent: September 1, 2015Assignee: NsGene A/SInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Publication number: 20150231208Abstract: The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.Type: ApplicationFiled: September 5, 2012Publication date: August 20, 2015Applicant: NSGENE A/SInventors: Jesper Roland Jorgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 9068015Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.Type: GrantFiled: December 14, 2012Date of Patent: June 30, 2015Assignee: NsGene A/SInventors: Jesper Roland Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
-
Publication number: 20140377341Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: ApplicationFiled: May 29, 2014Publication date: December 25, 2014Applicant: NsGene A/SInventors: Philip KUSK, Lars Ulrik Wahlberg
-
Patent number: 8815810Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: GrantFiled: March 14, 2013Date of Patent: August 26, 2014Assignee: NsGene A/SInventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 8741340Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.Type: GrantFiled: January 21, 2010Date of Patent: June 3, 2014Assignee: NsGene A/SInventors: Philip Kusk, Lars Ulrik Wahlberg
-
Publication number: 20130267464Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.Type: ApplicationFiled: December 14, 2012Publication date: October 10, 2013Applicant: NsGene A/SInventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
-
Publication number: 20130261543Abstract: According to an embodiment of the invention, an implantable cell device is disclosed. The device includes a membrane defining and enclosing a chamber; a distance means, within the chamber, for reducing diffusion distance for a biologically active factor to across the membrane; and a support means, within the chamber, for increasing cell support surface area per unit volume of the chamber for distributing cells.Type: ApplicationFiled: September 27, 2011Publication date: October 3, 2013Applicant: NsGene A/SInventors: Lars Ulrik Wahlberg, Jens Tornøe
-
Publication number: 20130109624Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: June 27, 2012Publication date: May 2, 2013Applicants: NSGENE A/S, BIOGEN IDEC MA INC.Inventors: Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Patent number: 8404642Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: GrantFiled: October 3, 2011Date of Patent: March 26, 2013Assignee: NsGene A/SInventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Publication number: 20120252726Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: April 11, 2011Publication date: October 4, 2012Applicant: NSGENE A/SInventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
-
Publication number: 20120184492Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein, NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and growth factor with antiapoptotic effects on a cell line with neuronal potential and with neuroprotective and/or neurogenesis effects on a neural precursor cell line and on primary striatal cultures. The invention also relates to novel bioactive NsG33 polypeptide fragments and the corresponding encoding DNA sequences.Type: ApplicationFiled: December 15, 2011Publication date: July 19, 2012Applicant: NsGene A/SInventors: Mette Grønborg, Philip Kusk, Nikolaj Blom, Thomas Nordahl Petersen, Teit E. Johansen, Soren Brunak, Lars U. Wahlberg
-
Patent number: 8217146Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: GrantFiled: December 7, 2009Date of Patent: July 10, 2012Assignees: Biogen Idec MA Inc., NsGene A/SInventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Publication number: 20120108518Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: ApplicationFiled: October 3, 2011Publication date: May 3, 2012Applicant: NsGene A/SInventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Publication number: 20120021039Abstract: The present application relates to expression constructs capable of securing correct processing of neuropeptides upon expression in mammalian cells, and to mammalian cells secreting correctly processed peptides. One exemplary peptide is galanin. The application also relates to devices containing neuropeptide secreting cells, which devices may be used for the treatment of epilepsy and other disorders of the nervous system. All references cited herein are incorporated by reference.Type: ApplicationFiled: January 21, 2010Publication date: January 26, 2012Applicant: NsGene A/SInventors: Philip Kusk, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 8088567Abstract: The present invention relates to an immortalized human neural precursor cell line, NGC-407. The cell line has been established from human foetal tissue. The cell line has been immortalized using a retroviral vector containing the v-myc oncogene. The cell line is a neural progenitor cell line capable of differentiating into to astrocytes and neurons including dopaminergic neurons. NGC-407 cells are capable of migrating to glioblastoma tumours implanted into rat brains and form gap junctions with the tumour cells. NGC-407 cells expressing a suicide gene can be be used for delivering activated prodrugs in the form of activated nucleoside analogs to tumours.Type: GrantFiled: March 30, 2006Date of Patent: January 3, 2012Assignee: NsGene A/SInventor: Bengt Juliusson